7月30日，据东方财经等多家媒体消息，在上午的说明会上，爱康国宾表示，张女士造谣令员工深受伤害，已向法院提起诉讼，法院已正式立案受理。爱 康集团董事长张黎刚表示，为了维护爱康员工的尊严，为了给行业正名，爱康不得不做出这个非常艰难的决定。 会上，爱康国宾公开回应张女士体检报告，并表示根据现有公开信息，北大医院病例报告明确标注是早期肾癌，而不是张女士所述的晚期。 爱康国宾相关负责人李秀池在说明会称，张女士在爱康国宾的十年体检均为北京律师协会提供的福利基础套餐。除2017年外，张女士没有自费购买任何特 色或升级项目。 李秀池表示，张女士2023年10月9日在北京爱康国宾西内门诊部参加健康体检，体检结果显示有肾错构瘤可能。爱康国宾建议"首次发现者需要做CT，以 除外其他肾脏占位性病变"，李秀池称，"除外其他肾脏占位性病变"即是提示癌症可能性。 爱康国宾还公布了张女士2023年10月9日在北京爱康国宾西内门诊部参加体检的部分报告，其中专家建议与指导部分显示：肾钙化灶和肾错构瘤可能。 会上，爱康国宾还回应了"体检到底有没有用"这一问题。爱康国宾方表示：体检的核心是发现风险信号，而不是做出最终诊断。体检的意义是通过检查项 ...

每经编辑｜陈柯名 7月30日，据东方财经等多家媒体消息，在上午的说明会上，爱康国宾表示，张女士造谣令员工深受伤害，已向法院提起诉讼，法院已正式立案受理。爱 康集团董事长张黎刚表示，为了维护爱康员工的尊严，为了给行业正名，爱康不得不做出这个非常艰难的决定。 爱康国宾相关负责人表示，当事人张女士罔顾事实，通过网络臆想造谣、污蔑爱康国宾"假体检"，并恶意发酵。此举严重损害爱康国宾声誉，深深伤害了 二十余年来专注健康服务的数万名员工，更误导公众，引发对私营体检中心、乃至整个中国医疗行业的不当质疑。为澄清事实，还原真相，爱康国宾已依 法向法院提起诉讼，目前案件已获正式立案。 图片来源：红星新闻 会上，爱康国宾公开回应张女士体检报告，并表示根据现有公开信息，北大医院病例报告明确标注是早期肾癌，而不是张女士所述的晚期。 爱康国宾相关负责人李秀池在说明会称，张女士在爱康国宾的十年体检均为北京律师协会提供的福利基础套餐。除2017年外，张女士没有自费购买任何特 色或升级项目。 李秀池表示，张女士2023年10月9日在北京爱康国宾西内门诊部参加健康体检，体检结果显示有肾错构瘤可能。爱康国宾建议"首次发现者需要做CT，以 除外其他 ...

Core Viewpoint - The controversy surrounding Aikang Guobin involves allegations of "fake health check-ups" after a lawyer, Zhang Xiaoling, was diagnosed with cancer despite years of normal test results from the company [1][2]. Group 1: Allegations and Responses - Zhang Xiaoling claims that Aikang Guobin's health checks failed to detect her cancer risk over a decade, leading to a late-stage diagnosis [1][2]. - Aikang Guobin has conducted internal and external evaluations, asserting that there were no misdiagnoses or false checks, and has initiated legal action against Zhang for defamation [2][6]. - The company emphasizes that health checks are not equivalent to medical diagnoses and are intended to identify potential health issues for further investigation by specialists [3]. Group 2: Medical Insights and Procedures - Aikang Guobin's medical professionals clarified that the 2023 ultrasound report indicated potential issues that warranted further examination, contradicting Zhang's claims [3][5]. - The company highlighted that cancer markers like carcinoembryonic antigen (CEA) are not reliable for early detection of kidney cancer, as imaging techniques are the primary diagnostic tools [5]. - Aikang Guobin maintains that it follows industry standards regarding the retention of blood samples, which typically last only 1-7 days, making it impossible to keep samples from the past decade [4]. Group 3: Impact on the Industry - The allegations have raised concerns about public trust in private health check-up centers and the broader healthcare industry in China, affecting the reputation of Aikang Guobin and its employees [6]. - The company asserts that the claims have harmed its reputation and the trust of its approximately 8 million annual clients [6].

Core Viewpoint - Aikang Guobin has initiated legal proceedings regarding a dispute over cancer screening with a client, Ms. Zhang, and the court has officially accepted the case [1] Group 1: Company Actions - Aikang Group's Senior Vice President, Zhou Xiaojiang, announced the lawsuit against Ms. Zhang during a press conference [1] - The company emphasizes the importance of seeking specialized medical advice if abnormalities are detected during health check-ups [1] Group 2: Industry Insights - Aikang Group's founder and CEO, Zhang Ligang, stated that cancer development is a gradual process and early detection may be limited by technological constraints [1] - The company highlights that health check-ups cannot replace specialized medical diagnosis and further examinations are necessary if any issues are found [1]

Core Viewpoint - The case of Zhang Xiaoling highlights significant concerns regarding the reliability of commercial health check-up services, particularly in cancer detection, raising questions about the effectiveness of routine screenings and the potential for misdiagnosis [2][4][27]. Group 1: Company and Service Reliability - Zhang Xiaoling underwent annual health check-ups at Aikang Guobin for ten years without being informed of any cancer risks, despite her eventual diagnosis of advanced kidney cancer [2][8]. - Aikang Guobin stated that they had reviewed Zhang's medical records and found no flaws in their kidney examinations, asserting their lack of responsibility in her case [3][7]. - The incident has sparked public debate about the trustworthiness of commercial health check-up institutions and the adequacy of cancer screening methods [4][27]. Group 2: Screening Limitations - Experts suggest that routine health check-ups primarily identify chronic diseases like hypertension and diabetes, with limited effectiveness in cancer detection [5][29]. - Various screening methods, such as ultrasound and CT scans, have inherent limitations, and a combination of different tests is recommended for more accurate results [5][19]. - The common use of tumor markers like CEA in screenings is criticized, as they are not reliable for early detection of certain cancers, including kidney cancer [11][12][14]. Group 3: Patient Experience and Misdiagnosis - Zhang's experience reflects a broader issue where patients report instances of missed cancer diagnoses despite normal results from commercial health check-ups [6][27]. - Misinterpretation of test results and inadequate communication from health check-up providers can lead to delayed diagnoses and treatment [16][18]. - The case emphasizes the need for better patient education regarding the significance of test results and the importance of follow-up examinations when abnormalities are detected [8][19]. Group 4: Recommendations for Improvement - Medical professionals recommend that individuals, especially those at higher risk, should seek more comprehensive evaluations, including advanced imaging techniques like CT or MRI, rather than relying solely on routine check-ups [30][31]. - Regular health screenings should be tailored to individual health profiles, considering factors such as age, family history, and existing health conditions [30][36]. - The importance of maintaining personal health records and undergoing early cancer screenings is emphasized to improve early detection rates and treatment outcomes [35][36].

Meeting Overview - The shareholders' meeting of Meinian Health Industry Holdings Co., Ltd. was held on July 28, 2025, with a total of 921 participants representing 1,277,900,984 shares, accounting for 32.6474% of the total shares [1] - The online voting took place from 9:15 AM to 3:00 PM on the same day, with 916 shareholders participating, representing 749,647,534 shares, or 19.1517% of the total shares [2] Voting Results - The meeting adopted resolutions with a significant majority, where 1,272,894,440 shares voted in favor, representing 99.6082% of the valid votes [2] - A total of 4,509,144 shares opposed the resolutions, accounting for 0.3529%, while 497,400 shares were abstained [2] Minority Shareholder Participation - Among the minority investors, 282,237,144 shares voted in favor, which is 98.2570% of the valid votes from minority shareholders [3] - The opposition from minority shareholders was 4,509,144 shares, representing 1.5698% [3] Related Party Transactions - The resolutions involved related party transactions, with specific shareholders, including Yu Rong and several asset management companies, abstaining from voting [3][4] - The voting results from non-related shareholders showed 738,065,801 shares in favor, which is 98.4550% of the valid votes [4] Detailed Voting Breakdown - The detailed voting results indicated that among non-related minority shareholders, 275,661,955 shares voted in favor, representing 95.9680% [4] - The opposition from this group was 11,086,633 shares, accounting for 3.8597% [4] Conclusion of Resolutions - All resolutions requiring a two-thirds majority from non-related shareholders were successfully passed according to the company's articles of association [4][5] - The resolutions included significant related party transactions, with the relevant shareholders abstaining from the voting process [5][6]

Core Viewpoint - The article highlights a charitable health screening event organized by Ciming Health Checkup Group for retired soldiers, emphasizing the importance of honoring and caring for veterans as a social responsibility and a way to express gratitude for their service [1][4][9]. Group 1: Event Overview - The "Welcoming August 1st, Warming Veterans" charity event took place on July 22, where 29 retired soldiers received health checkups, aiming to enhance their sense of honor, belonging, and happiness [1][4]. - Ciming Health Checkup Group, in collaboration with the Dahongmen Street Office, meticulously planned the event to ensure a memorable experience for the veterans [4][6]. Group 2: Health Services Provided - The health checkup included a comprehensive range of services tailored to the veterans' age and health needs, covering various medical specialties and tests such as internal medicine, external medicine, and cancer screenings [4][12]. - Medical staff provided personalized health guidance based on each veteran's health status, lifestyle, and medical history, ensuring a thorough and caring approach [4][12]. Group 3: Community and Corporate Responsibility - The event was praised by local officials, highlighting the importance of community support for veterans and the ongoing efforts to improve the service and support system for retired military personnel [6][8]. - Ciming Health Checkup Group has previously donated 1.68 million yuan for health checkups for low-income veterans, demonstrating a commitment to social responsibility and the well-being of retired soldiers [8][9]. Group 4: Future Initiatives - Ciming Health Checkup Group plans to continue expanding its charitable services, aiming to provide high-quality health services to a broader audience while fostering a culture of respect and care for veterans [12].

Core Viewpoint - The controversy surrounding Aikang Guobin's health check services has emerged after a lawyer, Zhang Xiaoling, claimed that her ten years of health check reports showed no cancer risk, yet she was later diagnosed with late-stage kidney cancer. This raises questions about the reliability of routine health checks and cancer screening methods [2][3][8]. Group 1: Company Response - Aikang Guobin has conducted internal reviews and external expert evaluations, asserting that they bear no responsibility for the alleged oversight in Zhang's health checks and are open to third-party assessments [11][18]. - The company stated that Zhang's 2023 report indicated a "right kidney calcification focus" and a "possible left kidney hamartoma," contradicting her claims of no abnormalities [8][11]. - Aikang emphasized that cancer detection is a complex process influenced by various factors, including the timing of tests and the methods used, and that some cancers may not be detectable at certain stages [19][20]. Group 2: Industry Insights - The cancer screening industry is evolving, with a projected market size of $20.82 billion in 2022, expected to reach $28.93 billion in 2023, highlighting the growing demand for effective early detection methods [26][27]. - Current cancer screening technologies primarily include X-rays, CT scans, MRI scans, and ultrasound, while advanced techniques like liquid biopsies and AI-assisted imaging are being developed [27]. - Experts recommend that individuals over 40 should undergo annual ultrasound checks for urinary system cancers, as conventional blood tests may not reliably indicate kidney cancer risk [20][21].

Core Viewpoint - The controversy surrounding Aikang Guobin's health check services has sparked public concern, particularly regarding the accuracy of cancer risk detection over a decade-long period [2][4]. Group 1: Incident Overview - A lawyer, Zhang Xiaoling, underwent health checks at Aikang Guobin for 10 consecutive years without any cancer warnings, only to be diagnosed with late-stage kidney cancer in 2024 [4]. - Zhang claims that Aikang Guobin failed to inform her of potential cancer risks despite a 2023 report indicating a "calcium spot" on her right kidney [4]. - After switching to a different health check provider, Zhang was diagnosed with kidney cancer, which had already metastasized to her bones by early 2025 [4]. Group 2: Company Response - Aikang Group stated that cancer detection depends on various factors, including the timing of the check, methods used, and the expertise of the medical staff [5]. - The company emphasized that their reports accurately reflect the results of the checks conducted at the time and that they would seek third-party verification if any responsibility is claimed [5]. - Aikang Group noted that Zhang's 2023 report did indicate potential issues, and the growth of her cyst from 2023 to 2024 fell within the range typical for cancer progression [5]. Group 3: Industry Context - Aikang Guobin has faced multiple complaints regarding inaccurate health reports and perceived negligence in their services, with over 1,300 complaints recorded on the Black Cat Complaint platform [6]. - The company was founded in 2004 and went public on NASDAQ in 2014, later privatizing in 2019 [9].

Core Viewpoint - The article discusses a controversy surrounding Aikang Group regarding the alleged failure to detect cancer risks in a client, leading to a late-stage kidney cancer diagnosis, raising questions about the effectiveness and reliability of their health check services [1][2]. Group 1: Company Response - Aikang Group issued a second statement confirming that their medical team reviewed the client's health records and found no diagnostic errors in the kidney examinations, asserting that their reports were accurate and consistent with ultrasound results [1][4]. - The company expressed willingness to accept third-party evaluations and take responsibility if found at fault, emphasizing their commitment to transparency and accountability [2][4]. Group 2: Client's Allegations - The client, lawyer Zhang Xiaoling, criticized Aikang's response as evasive, claiming it relied on "medical uncertainty" while neglecting systemic failures and data management issues [2][3]. - Zhang highlighted that Aikang had not provided requested documentation related to her health checks, including blood test data and the validity of specific cancer detection technologies [3][4]. Group 3: Importance of Professional Interpretation - Zhang argued that the value of health check services lies in the professional interpretation of results, which Aikang failed to provide, as clients often lack the medical knowledge to understand their reports [4]. - The company has a network of 170 health check centers across 54 cities in China, serving approximately 10 million individuals annually, indicating a significant scale of operations [4].